Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

MMWR: Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations--United States, 2001

This report provides preliminary information about 21 cases of liver injury associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations on selecting appropriate therapy for patients with latent TB infection and monitoring the use of RIF-PZA to treat infection.

Author:

Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR

Topic:

Treatment- Adverse Reactions, Case Management, Treatment Guidelines Materials, Treatment - Latent TB infection (Inactive TB), Treatment- Medication Information

Language:

English

Country of Origin:

United States

View Webpage

Related Materials

MMWR: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000

This report discusses two cases of latent TB infection in which patients developed severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment.

Report

Tuberculosis Drug-Induced Liver Injury

This webinar provides information that providers need to know when working with patients with compromised liver function due to taking TB medication.

Webinar

MMWR: Clinical Update: Impact of HIV Protease Inhibitors on the Treatment of HIV - Infected Tuberculosis Patients With Rifampin

This report describes approaches for managing patients with TB who are candidates for or who are undergoing protease inhibitor therapy and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued. Protease inhibitors interact with rifamycin derivatives, which are used to treat and prevent the mycobacterial infections commonly observed in patients with the HIV. The report provides background information on the management of TB and the three treatment options currently available for these patients. The concurrent use of protease inhibitors with rifampin might be possible by modifying the doses of both to compensate for the drug interaction.

Report

Global resources for the prevention,
management, and elimination of TB.